Asthma Symptom Control Using a Combination of Mometasone Furoate/Formoterol (MF/F) Grouped Analysis of Three Clinical Trials

M. White1, H. Nolte1, E. Meltzer1, R. Nathan1, 2Institute for Asthma & Allergy, Wheaton, MD, 3Schering-Plough, Kenilworth, NJ, 4Allergy and Asthma Medical Group and Research Center, San Diego, CA, 5Asthma and Allergy Associates and Research Center, Colorado Springs, CO.

RATIONAL: The efficacy of asthma treatments is typically quantified using FEV1 which does not always correlate with asthma symptoms and quality of life. We characterized the ability of mometasone furoate/formoterol (MF/F) combination to improve asthma control in adults/adolescents inadequately controlled on low-, medium-, and high-dose ICS.

METHODS: Changes from baseline to endpoint in Asthma Control Questionnaire (ACQ) scores were assessed in subjects from 3 Phase III trials [low- (n=746), medium- (n=781), and high-dose (n=728)]. The ACQ categorizes asthma symptoms and use of rescue medication using a 7-point scale (0=totally controlled, 6=severely uncontrolled). In the low- and medium-dose trials, subjects were randomized to receive MF/F (100/10 mcg or 200/10 mcg), MF (100 mcg or 200 mcg), F (10 mcg), or placebo (26 weeks; all BID). In the high-dose trial, subjects were randomized to receive MF/F 200/10 mcg, MF/F 400/10 mcg, or MF/F 400 mcg (12 weeks; all BID via MDI). RESULTS: Baseline ACQ scores (1.23-1.38, 1.41-1.47, and 1.83-1.87 in the low-, medium-, and high-dose trial, respectively) indicated that subjects in all trials were not well controlled (<0.75) on ICS monotherapy. MF/F yielded ACQ improvements (100/10 mcg vs. placebo: -0.07; 200/10 mcg vs. placebo: -0.11) and placebo (+0.24; +0.14). MF/F 400/10 mcg improved asthma control by -0.51 compared with -0.33 for MF 400 mcg monotherapy. Improvements for MF/F at all doses achieved minimal importance difference of >0.5 point increase.

CONCLUSION: MF/F showed clinically important improvement in asthma control at all strengths and was better than MF, F and placebo.

Effect of Mometasone Furoate/Formoterol (MF/F) Combination Therapy on Nocturnal Awakenings in Subjects With Persistent Asthma

D. Pearlman1, R. Nathan2, E. Meltzer3, H. Nolte4, S. Weinstein5, 1Colorado Allergy and Asthma Centers, Denver, CO, 2Asthma and Allergy Associates and Research Center, Colorado Springs, CO, 3Allergy & Asthma Medical Group & Research Center, San Diego, CA, 4Schering-Plough, Kenilworth, NJ, 5Allergy & Asthma Specialists Medical Group.

RATIONAL: Asthmatics often report asthma-related nocturnal awakenings. These sleep interruptions may have significant impact in patients’ quality of life. We characterized the effect of mometasone furoate/formoterol (MF/F) treatment on incidence of nocturnal awakenings requiring rescue-medication-use (SABA).

METHODS: MF/F’s effect on nocturnal awakenings requiring SABA was characterized across three Phase III efficacy trials (baseline=awakenings in week prior to first dose; endpoint=awakenings in last post-baseline Asthma-Control-Questionnaire result). Subjects were asthmatics previously treated with low- (n=746), medium- (n=781) or high-dose (n=728) ICS. Low-dose subjects were randomized to 26-weeks’ treatment with MF/F 100/10 mcg, MF 100 mcg, F 10 mcg, or placebo; medium-dose subjects to 26-weeks’ treatment with MF/F 200/10 mcg, MF 200 mcg, F 10 mcg, or placebo; high-dose subjects to 12-weeks’ treatment with MF/F 400/10 mcg, MF/F 200/10 mcg, or MF 400 mcg. All treatments were delivered twice-daily via MDI.

RESULTS: Baseline awakenings ranged from 0.84-1.05, 1.05-1.26, and 1.33-1.61 nights/week in the low-, medium-, and high-dose studies, respectively. In the low-dose study nocturnal awakenings were reduced by MF/F= -0.42, MF= -0.21, F= -0.21, and placebo=0.14 nights/week; corresponding changes in the medium-dose study were -0.56, -0.35, +0.07 and 0.00 night/week, respectively. In each of these placebo-controlled studies MF/F was superior to placebo (p<0.001) and F (p=0.035); MF/F was also superior to F and placebo. In the high-dose study, awakenings were reduced by -0.70, -0.70 and -0.35 nights/week by medium-dose MF/F, high-dose MF/F and high-dose MF, respectively; both MF/F treatments were superior to MF (p<0.006).

CONCLUSION: Both MF/F and MF significantly reduced nocturnal awakenings compared with F and placebo. Both doses of MF/F were superior to MF in the high-dose study.

The Particle Size of Mometasone Furoate 100 μg and 200 μg Dry Powder Formulations

R. Berger, S. Li, H. Staudinger; Schering-Plough Research Institute, Summit, NJ.

RATIONAL: Regional lung deposition of inhaled particles depends on particle size as well as inspiratory flow rate and other factors. Inhaled particles of aerodynamic size around 2 μm have been found to deposit most efficiently in the alveolar region across a broad range of inspiratory flow rates. In vivo studies of mometasone furoate (MF) delivered by the ‘Twisthaler’ showed mean peak inspiratory flow rates (PIFR) at satisfaction levels in adult/adolescent patients aged ≥12 years (69 L/min), children aged 9-12 years (>60 L/min), and children aged 5-8 years (>50 L/min). We report particle size findings from an in vitro study analyzing the mass median aerodynamic diameter (MMAD) of MF.

METHODS: Twelve inhalers of each the 110 and 220 μg/inhalation strengths were tested in vitro at the beginning and end of unit lives at a 60 L/min flow rate. Aerosolized MF was collected by cascade impaction for 2 inhalations from the 110 μg/inhalation strength and 1 inhalation from the 220 μg/inhalation strength, thereby providing similar particle masses.

RESULTS: The average MMAD of the 110 μg strength for beginning and ending inhalations (n=24) was 2.0 μm (range, 1.9-2.1 μm), while the 220 μg strength for beginning and ending inhalations (n=24) was 2.2 μm (range, 2.0-2.4 μm).

CONCLUSION: Average MMAD values of MF for both strengths measured in vitro at a clinically relevant flow rate, together with in vivo particle-size efficiency deposition models, suggest that the particle size of MF is optimal (~2 μm) for efficient alveolar deposition when administered via the Twisthaler.

Effect of Treatment with Mometasone Furoate/Formoterol Combination (MF/F) on Rescue Medication Use

C. LaForce1, E. Meltzer2, R. Nathan3, A. Nayak3, H. Nolte3, D. Pearlman4; 1Department of Pediatrics, University of North Carolina School of Medicine, North Carolina Clinical Research, Raleigh, NC, 2Allergy and Asthma Medical Group and Research Center, San Diego, CA, 3Allergy and Asthma Associates and Research Center, Colorado Springs, CO, 3Sneeze, Wheeze and Itch Associates, Normal, IL, 4Schering-Plough, Kenilworth, NJ, 5Colorado Allergy and Asthma Centers, Denver, CO.

RATIONAL: The use of rescue medication, such as short-acting β2-agonists (SABA), provides insight into disease control. We analyzed the effect of a new combination of mometasone furoate/formoterol (MF/F) on total daily use of SABA in subjects with asthma using data from two clinical trials.

METHODS: Asthma subjects (>12 years) previously treated with low-dose ICS (n=746) were randomized to 26 weeks twice-daily MDI treatment with MF/F (100/10 mcg), MF (100 mcg), F (10 mcg) or placebo. In a second trial of identical design, 781 subjects previously treated with medium-dose ICS, were randomized to MF/F (200/10 mcg), MF (200 mcg), F (10 mcg) or placebo. Using patient reported diary data, changes in mean AM/PM total rescue medication use (puffs + nebulizer) between baseline and endpoint were assessed.

RESULTS: In the low-dose trial, baseline use of rescue medication was: MF/F: 1.2, MF: 0.84, F: 1.14, and placebo: 1.03 daily puffs (+ nebulizer). Corresponding baseline use in the medium-dose trial were: MF/F: 2.02; MF: 1.64; F: 1.79; and placebo: 1.95. Changes in daily puffs of rescue medication in the low-dose trial were: MF/F (100/10 mcg) = -53.4%; MF (100 mcg) = -47.5%; F (+82.6%); and placebo: +47.5%. Changes in daily puffs of rescue medication in the medium-dose trial were: MF/F (200/10 mcg) = -61.1%; MF (200 mcg) = -22.1%; F: +184.1%, and placebo: +79.1%.

CONCLUSIONS: MF/F treatment reduced the use of rescue medication in subjects with persistent asthma previously treated with low- and medium-dose ICS monotherapy.